 |
|
 |
|
| MarketVIEW: Biodefense vaccines |
|
|
|
Published: September 2015
Since the 2001 terrorist attacks and continued threats at a global level against many Western governments, the concept of biodefense has become an important component of
many national countermeasure strategies. To this end, a number of chemical, biologica1 , radiological, and nuclear (CBRN) terrorism agents were identified as part of a new US law passed in
2004 known as the Project Bioshield Act. This act allowed the US government to guarantee a market for CBRN countermeasures, which up until June 2014 obligated approximately $3.309 bn in funding.
Despite Project Bioshield and The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), which has effectively extended the Project BioShield procurement program to FY2018, the US HHS has obligated 90% to just three threats: anthrax, smallpox, and botulinum toxin.
Project BioShield did not acquire any countermeasures against the other eight material CBRN threats, meaning that a significant amount of research and development is still required.
This MarketVIEW report covers in depth the background, legislation and current US capabilities with regard to biodefense vaccines with a focus on anthrax, smallpox and other biodefense vaccines. For anthrax and smallpox,
detailed coverage is provided on disease epidemiology, past and current vaccines/associated recommendations/policy and corporate development of new generation vaccines for inclusion to the future US Strategic National Stockpile.
The objective of this report is to give the reader a full background into the biodefense industry so that future dynamics/trends can be visualized for potential strategy development or market entry.
THIS PRODUCT IS A EXECUTIVE PRESENTATION
To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%.
Please review the TERMS and CONDITIONS of purchase.
|
|
|
|
|
|
